Jove
Visualize
Contact Us

Related Experiment Videos

Systemic chemotherapy for metastatic melanoma.

E F Mc Clay1, M J Mastrangelo

  • 1Division of Medical Oncology, Jefferson Medical College, Philadelphia.

Seminars in Oncology
|December 1, 1988
PubMed
Summary

Developing more effective treatments for metastatic melanoma is crucial. A four-drug combination including DTIC, BCNU, cisplatin, and tamoxifen shows promise with a 50% response rate and durable remissions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determinants of competency judgments by experienced laparoscopic surgeons.

Surgical endoscopy·2003
Same author

Evaluating minimally invasive surgery training using low-cost mechanical simulations.

Surgical endoscopy·2003
Same author

Obesity and laparoscopic repair of ventral hernias.

Surgical endoscopy·2002
Same author

Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases.

International journal of cancer·2001
Same author

Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer.

The Journal of urology·2001
Same author

Laparoscopic dissecting instruments.

Seminars in laparoscopic surgery·2001
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Oncology
  • Medical Oncology
  • Dermatology

Background:

  • Metastatic melanoma presents significant treatment challenges.
  • Current single-agent therapies often lack superior efficacy compared to dacarbazine (DTIC).
  • There is a critical need for novel and more effective therapeutic agents.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of novel treatment regimens for metastatic melanoma.
  • To assess the potential of combination chemotherapy and interferon-based therapies.

Main Methods:

  • Review of recent clinical experience with various chemotherapy agents and combinations.
  • Analysis of objective response rates, including complete remissions (CRs) and durable remissions.
  • Assessment of treatment tolerability and ease of administration.

Main Results:

  • A four-drug combination (DTIC, BCNU, cisplatin, tamoxifen) demonstrated an objective response rate of approximately 50%.
  • This regimen induced regressions in patients with visceral disease and occasional durable remissions up to 3 years.
  • Interferon alfa-2a showed a response rate of about 20%, with preliminary data on combination therapies being interesting.

Conclusions:

  • The four-drug combination regimen is a promising, well-tolerated, and easily administered option for metastatic melanoma.
  • Further investigation into detorubicin-containing regimens and the role of interferons in combination therapy is warranted.
  • High-dose cisplatin requires additional study before widespread clinical recommendation.

Related Experiment Videos